Psyence Biomedical And Optimi Health Sign Sign Non-Binding Letter Of Intent To Advance Global Psilocybin Drug Development; Agreement Would Make Optimi Exclusive Supplier Of GMP Non-Synthetic Psilocybin Extract For Psyence's Initiatives
Portfolio Pulse from Benzinga Newsdesk
Psyence Biomedical and Optimi Health have signed a non-binding letter of intent to collaborate on global psilocybin drug development. Optimi Health will become the exclusive supplier of GMP non-synthetic psilocybin extract for Psyence's initiatives.
August 13, 2024 | 11:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Psyence Biomedical has signed a non-binding letter of intent with Optimi Health to advance global psilocybin drug development. Optimi will be the exclusive supplier of GMP non-synthetic psilocybin extract for Psyence's initiatives.
The agreement positions Psyence Biomedical to advance its psilocybin drug development initiatives with a reliable supply of GMP non-synthetic psilocybin extract, potentially accelerating its research and development efforts.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100